問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Hematology & Oncology

Division of Urology

更新時間：2023-09-19

洪士鈞
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

8Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

洪士鈞

List

10Cases

2017-09-26 - 2022-12-31

Phase III

Completed
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Terminated5Sites

蘇柏榮
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

顏厥全
Taipei Veterans General Hospital

Division of Hematology & Oncology

2018-06-15 - 2021-06-30

Phase III

Completed
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
6Sites

Recruiting6Sites

林永昌
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2019-05-19 - 2027-01-25

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
4Sites

Recruiting4Sites

2018-10-30 - 2022-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting10Sites

2018-02-05 - 2022-12-31

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Terminated9Sites

馮思中
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2018-09-28 - 2026-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting7Sites

2019-06-01 - 2024-07-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2020-07-22 - 2025-11-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2020-07-22 - 2027-11-10

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2018-04-30 - 2022-10-31

Phase II/III

A Randomized, Open Label, Multicenter Phase 2/3 Study to Evaluate the Efficacy and Safety of Rogaratinib (BAY1163877) Compared to Chemotherapy in Patients With FGFR-positive Locally Advanced or Metastatic Urothelial Carcinoma Who Have Received Prior Platinum-containing Chemotherapy

  • Condition/Disease

    FGFR-positive Locally Advanced or Metastatic Urothelial Carcinoma Who Have Received Prior Platinum-containing Chemotherapy

  • Test Drug

    BAY 1163877

Participate Sites
7Sites

Terminated6Sites

馮思中
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB